News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

BESPONSA® (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, available for order at Biologics, Inc.

CARY, N.C. (August 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA® (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Approved by t… Read More

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

CARY, N.C. (July 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment… Read More

Biologics, Inc. Earns Prestigious URAC Accreditation for Specialty Pharmacy

Rigorous accreditation process helps ensure high-quality care, ongoing process improvement and optimal outcomes CARY, N.C. (June 27, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation from URAC, the healthcare industry’s leading certification and accreditation organization that evaluates quality standards. The independent non-profit organization promotes quality by ensuring… Read More

Biologics’ Patient Access Services Team Procures more than $44 Million in Co-pay Assistance for Cancer Patients in 2016

CARY, N.C. (May 24, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, secured more than $44 million in co-pay assistance in 2016 for commercial patients in need of oral chemotherapy drugs, easing the financial burden for these patients battling cancer. The Biologics’ Patient Access Services team also referred more than 38,000 unique patients to… Read More

IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (May 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be a specialty pharmacy provider in the limited distribution network for IMFINZITM (durvalumab). In addition to being available via specialty distribution, IMFINZI can also be dispensed by Biologics as a specialty pharmacy option. Approved… Read More

ALUNBRIG (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (May 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM (brigatinib). ALUNBRIG, an oral therapy for the treatment of patients wit… Read More

RYDAPT® (midostaurin) Approved for the Treatment of FLT3-Mutated Acute Myeloid Leukemia, Available for Order at Biologics, Inc.

CARY, N.C. (May 3, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Novartis to be in the distribution network for RYDAPT® (midostaurin), a new oral treatment for adults with newly-diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. The AML treatment strategy has remained virtually… Read More

Biologics, Inc. Selected by TESARO as a Specialty Pharmacy Provider for ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

CARY, N.C. (April 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by TESARO, Inc. to be a specialty pharmacy provider in the distribution network for ZEJULATM (niraparib). Approved by the U.S. Food and Drug Administration (FDA) on March 27, 2017, ZEJULA is a poly ADP-ribose polymerase (PARP) inhibitor,… Read More

BAVENCIO® (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics, Inc.

CARY, N.C. (March 28, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by EMD Serono to be a specialty pharmacy provider for BAVENCIO (avelumab). Approved by the U.S. Food and Drug Administration (FDA) on March 23, 2017, BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for t… Read More

KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.

CARY, N.C. (March 17, 2017) —Biologics, Inc. a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI® (ribociclib). Approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017, KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as… Read More